scholarly journals Onset of puberty and near adult height in short children born small for gestational age and treated with GH: Interim analysis of up to 10 years of treatment in Japan

2015 ◽  
Vol 24 (2) ◽  
pp. 67-67
Author(s):  
Toshiaki Tanaka ◽  
Susumu Yokoya ◽  
Yoshiki Seino ◽  
Hiroshi Tada ◽  
Jun Mishina ◽  
...  
Keyword(s):  
Gestational Age ◽  
Small For Gestational Age ◽  
Interim Analysis ◽  
Adult Height ◽  
Short Children

Adult height in short children born small for gestational age treated with growth hormone

2020 ◽  
Vol 154 (8) ◽  
pp. 289-294
Author(s):  
Anunciación Beisti Ortego ◽  
Cristina Fuertes Rodrigo ◽  
Marta Ferrer Lozano ◽  
José Ignacio Labarta Aizpun ◽  
Antonio de Arriba Muñoz
Keyword(s):  
Growth Hormone ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Adult Height ◽  
Short Children

scholarly journals Adult height of prepubertal short children born small for gestational age treated with GH

2005 ◽  
Vol 152 (6) ◽  
pp. 835-843 ◽  
Author(s):  
Myriam Rosilio ◽  
Jean-Claude Carel ◽  
Emmanuel Ecosse ◽  
Jean-Louis Chaussainon ◽  
_ _
Keyword(s):  
Treatment Period ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Adult Height ◽  
Growth Potential ◽  
Phase Iii ◽  
Efficacy And Safety ◽  
Normal Range ◽  
Short Children ◽  
Height Gain

Objective: Human GH (hGH) treatment leads to catch-up growth in children with short stature born small for gestational age (SGA). However, long-term efficacy and safety results in this patient group remain scarce. The present study assessed the efficacy and safety of late childhood treatment with biosynthetic hGH (Humatrope) in a group of short children born SGA (height <−2 standard deviation scores (SDS)). Design: Patients in this open-label, Phase III, multicenter study received a daily hGH dose of 0.067 mg/kg for 2 years, and then received no treatment for the following 2 years. After the fourth year on study, patients whose height had decreased more than 0.5 SDS but who still showed growth potential based on bone age were allowed to resume treatment until they reached adult height. Methods: Height gain SDS was assessed for 11 girls and 24 boys (mean age±s.d. 9.6±0.9 years) at the end of the 2 years of hGH treatment, during the subsequent 2-year off-treatment period, and upon reaching adult height. Results: At the end of the initial 2-year treatment period, 83% of patients had reached a height within the normal range, with a mean increase in height SDS vs baseline of 1.3±0.3 (P <0.001). Adult heights (n = 20) were within the normal range for 50% of patients, and mean height gain from baseline was statistically significant (0.7±0.8 SDS, P <0.001). Fasting glucose and glycosylated hemoglobin levels were not significantly modified during treatment. Conclusions: High-dose hGH treatment for a minimum of 2 years in short children born SGA was well tolerated and resulted in a significant increase in adolescent and adult height.

scholarly journals New Horizons in Short Children Born Small for Gestational Age

2021 ◽  
Vol 9 ◽  
Author(s):  
Irène Netchine ◽  
Manouk van der Steen ◽  
Abel López-Bermejo ◽  
Ekaterina Koledova ◽  
Mohamad Maghnie
Keyword(s):  
Gestational Age ◽  
Small For Gestational Age ◽  
Adult Height ◽  
Growth Spurt ◽  
Metabolic Abnormalities ◽  
Gh Treatment ◽  
Short Children ◽  
Increased Risk ◽  
Catch Up ◽  
Silver Russell Syndrome

Children born small for gestational age (SGA) comprise a heterogeneous group due to the varied nature of the cause. Approximately 85–90% have catch-up growth within the first 4 postnatal years, while the remainder remain short. In later life, children born SGA have an increased risk to develop metabolic abnormalities, including visceral adiposity, insulin resistance, and cardiovascular problems, and may have impaired pubertal onset and growth. The third “360° European Meeting on Growth and Endocrine Disorders” in Rome, Italy, in February 2018, funded by Merck KGaA, Germany, included a session that examined aspects of short children born SGA, with three presentations followed by a discussion period, on which this report is based. Children born SGA who remain short are eligible for GH treatment, which is an approved indication. GH treatment increases linear growth and can also improve some metabolic abnormalities. After stopping GH at near-adult height, metabolic parameters normalize, but pharmacological effects on lean body mass and fat mass are lost; continued monitoring of body composition and metabolic changes may be necessary. Guidelines have been published on diagnosis and management of children with Silver-Russell syndrome, who comprise a specific group of those born SGA; these children rarely have catch-up growth and GH treatment initiation as early as possible is recommended. Early and moderate pubertal growth spurt can occur in children born SGA, including those with Silver-Russell syndrome, and reduce adult height. Treatments that delay puberty, specifically metformin and gonadotropin releasing hormone analogs in combination with GH, have been proposed, but are used off-label, currently lack replication of data, and require further studies of efficacy and safety.

scholarly journals One-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age

2014 ◽  
Vol 4 (1-2) ◽  
pp. 1-13 ◽  
Author(s):  
Hans-Peter Schwarz ◽  
Dorota Birkholz-Walerzak ◽  
Mieczyslaw Szalecki ◽  
Mieczyslaw Walczak ◽  
Corina Galesanu ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Short Children ◽  
One Year ◽  
Phase Iv
Sign in / Sign up

Export Citation Format

Share Document